NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/05/2026 15:38
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization37.69 mln
Float3.64 mln
Earnings Date05/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-3.05
Reliable
1-Year Forecast
65.80
Transformational upside
Relative Strength
21
/ 100
Significantly lagging
Debt / Equity
0.10
Very low leverage
ROE
-38.44
Deeply negative
Business Description
Aligos Therapeutics is a clinical-stage company working to develop new medicines for patients with serious liver and viral diseases that currently have limited treatment options. Founded in 2018 and based in South San Francisco, the company has several drug candidates advancing through clinical trials, targeting conditions such as fatty liver disease, obesity, hepatitis B, and coronavirus infections. Aligos works alongside research partners including Emory University and KU Leuven to support its drug discovery and development efforts.
